  The `Laser-hybrid Accelerator for Radiobiological Applications', LhARA, is
conceived as a novel, uniquely-flexible facility dedicated to the study of
radiobiology. The technologies demonstrated in LhARA, which have wide
application, will be developed to allow particle-beam therapy to be delivered
in a completely new regime, combining a variety of ion species in a single
treatment fraction and exploiting ultra-high dose rates. LhARA will be a hybrid
accelerator system in which laser interactions drive the creation of a large
flux of protons or light ions that are captured using a plasma (Gabor) lens and
formed into a beam. The laser-driven source allows protons and ions to be
captured at energies significantly above those that pertain in conventional
facilities, thus evading the current space-charge limit on the instantaneous
dose rate that can be delivered. The laser-hybrid approach, therefore, will
allow the vast ``terra incognita'' of the radiobiology that determines the
response of tissue to ionising radiation to be studied with protons and light
ions using a wide variety of time structures, spectral distributions, and
spatial configurations at instantaneous dose rates up to and significantly
beyond the ultra-high dose-rate `FLASH' regime.
  It is proposed that LhARA be developed in two stages. In the first stage, a
programme of in vitro radiobiology will be served with proton beams with
energies between 10MeV and 15MeV. In stage two, the beam will be accelerated
using a fixed-field accelerator (FFA). This will allow experiments to be
carried out in vitro and in vivo with proton beam energies of up to 127MeV. In
addition, ion beams with energies up to 33.4MeV per nucleon will be available
for in vitro and in vivo experiments. This paper presents the conceptual design
for LhARA and the R&D programme by which the LhARA consortium seeks to
establish the facility.
